Immutep Limited (IMMP)
After hours:
Chart Events
Performance Outlook
| Previous Close | 2.0400 |
| Open | 2.1000 |
| Bid | 2.0700 x 900 |
| Ask | 2.2600 x 1400 |
| Day's Range | 2.0600 - 2.1000 |
| 52 Week Range | 1.8500 - 5.0000 |
| Volume | |
| Avg. Volume | 104,429 |
| Market Cap | 189.196M |
| Beta (5Y Monthly) | 1.90 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for IMMP
Related Research
- Immutep LimitedDaily – Vickers Top Insider Picks for 07/19/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.RatingFair ValueEconomic Moatlast monthArgus Research
- GlobeNewswire
Immutep Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2nd Line PD-X Refractory NSCLC
Encouraging efficacy results continue for patients with 2nd line PD-X refractory non-small cell lung cancer (NSCLC)Patients in this 2nd line setting had confirmed disease progression on anti-PD-1 / anti-PD-L1 (“PD-X”) based 1st line therapy1Key facts reported: Median Overall Survival (OS) from therapy with efti in combination with pembrolizumab is 9.7 months25% were progression free at 6 months and 36.5% were alive at 18 months2 Chemo-free therapy of efti in combination with pembrolizumab contin
- GlobeNewswire
Immutep Quarterly Activities Report
Phase II TACTI-002 trial met its primary objective in 1st line non-small cell lung cancer (NSCLC) patients, with 38.6% Overall Response Rate and favourable anti-tumour activityBiomarker and multivariate analysis data from the completed Phase IIb AIPAC trial reported, confirming efti is activating the immune system and helping patients live longerFour world leading oncologists join the Clinical Advisory BoardWell-funded with ~$80 million in cash, giving Immutep an expected cash runway into early
- GlobeNewswire
Immutep Granted Japanese Patent for IMP761, A First-In-Class Immunosuppressive Antibody Targeting Lag-3
SYDNEY, AUSTRALIA, July 06, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce the grant of a new patent (number 7074341) entitled “Anti-LAG-3 Antibodies” by the Japanese Patent Office. This new Japanese patent follows the grant of the equivalent European patent announced in October 2020. The claims of the patent are directed to
